Alkermes plc (ALKS): Net earnings per share for the last 12 months

Symbol and logo of brand Alkermes plc (ALKS)

Alkermes plc (ALKS) is driving its development vector through an active R&D pipeline focused on oncology and schizophrenia treatment. The trailing twelve-month earnings per share on the GURU.Markets chart demonstrates current cash flow stability, with the indicator standing at -0.01. This confirms the brand's authority in neurology and the effectiveness of its patented extended-release drug delivery systems, which protect profits from competition.

ALKS (Alkermes Corp) Net earnings per share for the last 12 months history from 07/04/2022 to 11/12/2026

Analytical breakdowns and data insights for company Alkermes PLC (ALKS)

- current quotes and average value forecast:
Price Chart Alkermes plc|ALKS - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Alkermes plc|ALKS - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Alkermes|ALKS - Company Net Assets|Market Capitalization to Book Value Ratio alkermes.com|ALKS - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Alkermes plc|ALKS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Alkermes Inc.|ALKS - Company Aggregate Debts|Debt to Book Capitalization Ratio Alkermes plc|ALKS - Company Long-Term Debt|Company Short-Term Debt Alkermes|Quick Ratio alkermes.com
- net income and valuation multiples indicators:
ALKS - Company Net Income|Expected Profit Alkermes plc|ALKS - Company Value to Net Income|Future Price to Earnings Alkermes|ALKS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Alkermes plc|ALKS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Alkermes|ALKS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months alkermes.com|ALKS - Earnings per share increase in current year|Net earnings per share growth forecast for next year Alkermes plc
Analysis of all company metrics:ALKS - Alkermes plc
Mass-produced product of Alkermes PLC

The specifics of Alkermes plc (ALKS) necessitate significant expenditures for the specialized transportation of psychotropic agents, which directly impacts final margins. By analyzing the net earnings per share over the last four quarters, an investor sees the result of dividing the total annual income by the number of shares, which allows for an assessment of the business's real yield without time lags and determines the degree of the asset's overvaluation.

Competitor analysis for Alkermes plc

AVDL - Earnings per share for the last twelve months|Net earnings per share for the last four quarters atai.life ATAI|GHRS (GH Research) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Mind Medicine (MindMed) Inc. (MNMD)|CMPS (Compass Pathways) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months LB Corp (LBRX)|Net earnings per share (EPS TTM) DRUG|VNDA (vandapharma.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Cybin CYBN|Alto Neuroscience Inc (ANRO) - Net earnings per one share for the last twelve months|NRx Pharma - Net earnings per share (EPS TTM)|CING - Net earnings per share (EPS TTM)|Silo Pharma, Inc. (SILO) - Earnings per share for the last twelve months|CPHI (China Pharma Holdings, Inc.) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Clearmind Medicine|Net earnings per share (EPS TTM) Psyence Biomedical Ltd|Net earnings per share (EPS TTM) SPRC|SEEL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Virpax Pharmaceuticals, Inc. VRPX|Earnings per share for the trailing year KRTX